


## Morinidazole

<b>Cat. No.:</b>	HY-15781		
<b>CAS No.:</b>	92478-27-8		
<b>Molecular Formula:</b>	C <sub>11</sub> H <sub>18</sub> N <sub>4</sub> O <sub>4</sub>		
<b>Molecular Weight:</b>	270.29		
<b>Target:</b>	Bacterial		
<b>Pathway:</b>	Anti-infection		
<b>Storage:</b>	Powder	-20°C	3 years
		4°C	2 years
	In solvent	-80°C	6 months
		-20°C	1 month



### SOLVENT & SOLUBILITY

#### In Vitro

DMSO : ≥ 100 mg/mL (369.97 mM)  
 \* "≥" means soluble, but saturation unknown.

Preparing Stock Solutions	Solvent Concentration	Mass		
		1 mg	5 mg	10 mg
	1 mM	3.6997 mL	18.4986 mL	36.9973 mL
	5 mM	0.7399 mL	3.6997 mL	7.3995 mL
	10 mM	0.3700 mL	1.8499 mL	3.6997 mL

Please refer to the solubility information to select the appropriate solvent.

#### In Vivo

- Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline  
 Solubility: ≥ 2.75 mg/mL (10.17 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline)  
 Solubility: ≥ 2.75 mg/mL (10.17 mM); Clear solution
- Add each solvent one by one: 10% DMSO >> 90% corn oil  
 Solubility: ≥ 2.75 mg/mL (10.17 mM); Clear solution

### BIOLOGICAL ACTIVITY

#### Description

Morinidazole is a novel 5-nitroimidazole antimicrobial drug that undergoes extensive metabolism in humans via N+glucuronidation and sulfation, for the treatment of bacterial infections including appendicitis and pelvic inflammatory disease (PID) caused by anaerobic bacteria.

### REFERENCES

---

[1]. Zhong K, et al. Effects of renal impairment on the pharmacokinetics of morinidazole: uptake transporter-mediated renal clearance of the conjugated metabolites. Antimicrob Agents Chemother. 2014 Jul;58(7):4153-61.

---

**Caution: Product has not been fully validated for medical applications. For research use only.**

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: [tech@MedChemExpress.com](mailto:tech@MedChemExpress.com)

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA